IN2014DN07888A - - Google Patents

Info

Publication number
IN2014DN07888A
IN2014DN07888A IN7888DEN2014A IN2014DN07888A IN 2014DN07888 A IN2014DN07888 A IN 2014DN07888A IN 7888DEN2014 A IN7888DEN2014 A IN 7888DEN2014A IN 2014DN07888 A IN2014DN07888 A IN 2014DN07888A
Authority
IN
India
Prior art keywords
nanostructures
cells
compositions
cases
conditions
Prior art date
Application number
Other languages
English (en)
Inventor
C Shad Thaxton
Marina G Damiano
Heng Zhang
Kaylin M Mcmahon
Shuo Yang
Leo I Gordon
Amareshwar T K Singh
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of IN2014DN07888A publication Critical patent/IN2014DN07888A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Ceramic Engineering (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IN7888DEN2014 2012-02-22 2013-02-22 IN2014DN07888A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261601706P 2012-02-22 2012-02-22
PCT/US2013/027431 WO2013126776A1 (en) 2012-02-22 2013-02-22 Nanostructures for treating cancers and other conditions

Publications (1)

Publication Number Publication Date
IN2014DN07888A true IN2014DN07888A (pt) 2015-04-24

Family

ID=47833440

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7888DEN2014 IN2014DN07888A (pt) 2012-02-22 2013-02-22

Country Status (11)

Country Link
US (1) US20150064255A1 (pt)
EP (2) EP3597209A1 (pt)
JP (1) JP2015513543A (pt)
KR (1) KR20140123597A (pt)
CN (1) CN104244965A (pt)
AU (1) AU2013222238A1 (pt)
CA (1) CA2865279C (pt)
ES (1) ES2745208T3 (pt)
IN (1) IN2014DN07888A (pt)
MX (1) MX2014010161A (pt)
WO (1) WO2013126776A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006241123B2 (en) 2005-04-25 2013-10-03 Massachusetts Institute Of Technology Compositions and methods for promoting hemostasis and other physiological activities
DK2012842T3 (en) 2006-04-25 2018-05-28 Massachusetts Inst Technology COMPOSITIONS AND PROCEDURES TO INFLUENCE THE MOVEMENT OF CONTAMINANTS, BODIES, OR OTHER UNITS AND / OR TO INFLUENCE OTHER PHYSIOLOGICAL CONDITIONS
EP2288336B8 (en) 2008-04-25 2017-03-22 Northwestern University Nanostructures suitable for sequestering cholesterol
US9439941B2 (en) 2009-12-14 2016-09-13 The University Of Hong Kong Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells
AU2011207563B2 (en) 2010-01-19 2016-03-10 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
EP2946014A2 (en) 2013-01-17 2015-11-25 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
JP6697384B2 (ja) 2013-07-25 2020-05-20 イグジキュア, インコーポレーテッドExicure, Inc. 予防的および治療的使用のための免疫刺激剤としての球状の核酸ベース構築物
WO2015023797A1 (en) * 2013-08-13 2015-02-19 Northwestern University Lipophilic nanoparticles for drug delivery
US10413565B2 (en) 2014-04-30 2019-09-17 Northwestern University Nanostructures for modulating intercellular communication and uses thereof
WO2016011049A2 (en) * 2014-07-14 2016-01-21 Schwendeman Anna Compositions and methods for disease treatment using nanoparticle delivered compounds
AU2015328242A1 (en) 2014-10-06 2017-04-27 Exicure, Inc. Anti-TNF compounds
US10517924B2 (en) * 2014-11-24 2019-12-31 Northwestern University High density lipoprotein nanoparticles for inflammation
WO2016123365A1 (en) 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Liposomal particles comprising biological molecules and uses thereof
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
MX2017012131A (es) 2015-03-25 2018-06-15 Univ Michigan Regents Composiciones y métodos para la administración de agentes de biomacromoléculas.
US10967072B2 (en) 2016-04-27 2021-04-06 Northwestern University Short interfering RNA templated lipoprotein particles (siRNA-TLP)
EP3914236A4 (en) * 2019-01-24 2022-10-26 Northwestern University HIGH-DENSITY LIPOPROTEINMIMETIC NANOPARTICLES USING LIPID-CONJUGATED CORE SCAFFOLDINGS
EP3958843A4 (en) * 2019-04-26 2023-02-22 Northwestern University HIGH DENSITY LIPOPROTEIN NANOPARTICLES AND RNA MATRIX LIPOPROTEIN PARTICLES FOR OCULAR THERAPY
WO2020231860A1 (en) * 2019-05-10 2020-11-19 Northwestern University Orally delivered lipid nanoparticles target and reveal gut cd36 as a master regulator of systemic lipid homeostasis with differential gender responses
WO2021055788A1 (en) * 2019-09-18 2021-03-25 Northwestern University High density lipoprotein-like nanoparticles as inducers of ferroptosis in cancer
CN112569207A (zh) * 2019-09-30 2021-03-30 复旦大学 一种载脂蛋白修饰的仿生纳米肿瘤疫苗及其制备方法和用途
KR102614058B1 (ko) * 2022-06-13 2023-12-15 (주) 멥스젠 약물전달용 재구축 고밀도 지단백 나노입자

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1986699A4 (en) * 2006-01-26 2010-12-15 Univ Massachusetts RNA INTERFERENCE AGENTS FOR THERAPEUTIC USE
CA2708719A1 (en) * 2007-12-12 2009-06-18 University Health Network High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles
EP2288336B8 (en) 2008-04-25 2017-03-22 Northwestern University Nanostructures suitable for sequestering cholesterol
AU2011207563B2 (en) * 2010-01-19 2016-03-10 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities

Also Published As

Publication number Publication date
CA2865279C (en) 2023-04-25
CA2865279A1 (en) 2013-08-29
KR20140123597A (ko) 2014-10-22
EP2817024B1 (en) 2019-07-10
ES2745208T3 (es) 2020-02-28
JP2015513543A (ja) 2015-05-14
WO2013126776A1 (en) 2013-08-29
AU2013222238A1 (en) 2014-09-18
US20150064255A1 (en) 2015-03-05
EP2817024A1 (en) 2014-12-31
EP3597209A1 (en) 2020-01-22
MX2014010161A (es) 2015-03-09
CN104244965A (zh) 2014-12-24

Similar Documents

Publication Publication Date Title
IN2014DN07888A (pt)
MY166014A (en) Combination therapy methods for treating proliferative diseases
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
UA99839C2 (ru) Бензодиазепиноновые соединения, применяемые при лечении кожных состояний
MX359327B (es) Composiciones y sus usos para tratar y prevenir la enfermedad de huntington.
MY162903A (en) Methods of treatment of pancreatic cancer
PH12015500879A1 (en) Compositions and methods for treating proteinopathies
EP3587558A3 (en) Methods of populating a gastrointestinal tract
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
SG10201907588XA (en) Androgen Receptor Modulators And Uses Thereof
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
IN2015KN00414A (pt)
PE20150223A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
SG10201808661XA (en) Method of treating obesity using antioxidant inflammation modulators
MX362185B (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
MX2012010434A (es) Compuestos y composiciones novedosas para atacar a las celulas madre del cancer.
GB201318761D0 (en) Compounds for the treatment of neuropsychiatric disorders
WO2010132697A3 (en) Methods and compositions for treatment
WO2012170947A3 (en) Methods for modulating factor 12 expression
IN2014CN03610A (pt)
DK2714888T3 (da) Rekombinant gær
MX365392B (es) Composición de combinación de pac-1 y doxorrubicina.
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
MX2013010524A (es) Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata.
MX366380B (es) Composiciones prebioticas para el cuidado oral que contienen un alquilglucosido.